Weekly Investment Analysts’ Ratings Changes for Natera (NTRA)

Several analysts have recently updated their ratings and price targets for Natera (NASDAQ: NTRA):

• 7/17/2026 – Natera had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Natera had its “buy” rating reaffirmed by TD Cowen.
• 7/14/2026 – Natera was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/14/2026 – Natera had its price target raised by Canaccord Genuity Group Inc. from $285.00 to $330.00. They now have a “buy” rating on the stock.
• 7/9/2026 – Natera had its price target raised by Morgan Stanley from $250.00 to $310.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – Natera had its “outperform” rating reaffirmed by Evercore Inc. They now have a $300.00 price target on the stock.
• 6/29/2026 – Natera had its price target raised by Guggenheim from $270.00 to $290.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Natera is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $310.00 price target on the stock.
• 6/25/2026 – Natera was upgraded by Sanford C. Bernstein to “strong-buy”.
• 6/24/2026 – Natera was given a new $275.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 6/24/2026 – Natera was given a new $260.00 price target by UBS Group AG.
• 6/24/2026 – Natera had its price target lowered by Barclays PLC from $280.00 to $260.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Natera had its price target raised by BTIG Research from $250.00 to $270.00. They now have a “buy” rating on the stock.
• 6/11/2026 – Natera is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $275.00 price target on the stock.
• 6/5/2026 – Natera is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $245.00 price target on the stock.
• 6/5/2026 – Natera is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $245.00 price target on the stock.
• 6/2/2026 – Natera is now covered by Wolfe Research. They set an “outperform” rating and a $260.00 price target on the stock.
• 6/1/2026 – Natera was upgraded by Wolfe Research to “strong-buy”.

Insider Activity

In other Natera news, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director directly owned 4,250 shares in the company, valued at $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rowan E. Chapman sold 2,964 shares of Natera stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the sale, the director directly owned 3,124 shares in the company, valued at approximately $677,220.72. The trade was a 48.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 167,171 shares of company stock worth $37,239,209. 5.05% of the stock is owned by company insiders.

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.